Keyphrases
Acute Coronary Event
25%
Adverse Events
25%
Adverse Experiences
25%
Air Force
100%
Atherosclerosis Prevention
100%
Cancer Analysis
25%
Cancer History
25%
Cancer Incidence
25%
Cardiovascular Events
25%
Clinically Significant
50%
Confidence Interval
75%
Coronary Atherosclerosis
100%
Coronary Heart Disease Prevention
25%
Creatine Phosphokinase
50%
CYP3A4 Inhibition
25%
Cytochrome P450 Isoforms
25%
Event History
25%
Group Differences
25%
Hepatic Transaminases
50%
High-density Lipoprotein Cholesterol (HDL-C)
25%
Intention-to-treat
25%
Long-term Safety
25%
Long-term Treatment
100%
Lovastatin
100%
Low-density Lipoprotein Cholesterol (LDL-C)
50%
Major Coronary Events
25%
Middle-aged
50%
No Significant Difference
25%
Non-cardiovascular
50%
Non-cardiovascular Mortality
25%
Nonfatal Myocardial Infarction
25%
Older Men
25%
Older Women
25%
Physical Laboratory
25%
Placebo
25%
Point Analysis
25%
Prevention Studies
100%
Primary Prevention
25%
Primary Prevention Trials
25%
Randomized Placebo-controlled Trial
25%
Relative Risk
75%
Safety Data
25%
Safety Monitoring
25%
Stable Angina
25%
Sudden Death
25%
Texas
100%
Tolerability
100%
Treatment Group
50%
Vital Status
25%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
20%
Aminotransferase
40%
Coronary Artery Atherosclerosis
100%
Creatine Kinase
40%
CYP3A4
20%
Cytochrome P450
20%
Heart Infarction
20%
High Density Lipoprotein Cholesterol
20%
Ischemic Heart Disease
20%
Low Density Lipoprotein Cholesterol
40%
Malignant Neoplasm
100%
Mevinolin
100%
Placebo
40%
Sudden Death
20%
Tolerability
100%
Unstable Angina Pectoris
20%